biostudies-literatureUnknown333(9)Zeng Z<h4>Importance</h4>Previous studies have demonstrated the advantages of short-term histopathological outcomes and complications associated with transanal total mesorectal excision (TME) compared with laparoscopic TME. However, the long-term oncological outcomes of transanal TME remain ambiguous. This study aims to compare 3-year disease-free survival of transanal TME with laparoscopic TME.<h4>Objective</h4>To evaluate 3-year disease-free survival between transanal TME and laparoscopic TME in patients with rectal cancer.<h4>Design, setting, and participants</h4>This randomized, open-label, noninferiority, phase 3 clinical trial was performed in 16 different centers in China. Between April 2016 and June 2021, a total of 1115 patients with clinical stage I to III mid-low rectal cancer were enJAMA774-783https://www.ebi.ac.uk/biostudies/studies/S-EPMC11880948biostudies-literatureTransanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial.PMC11880948Wu MShi LZheng HCZhang HZhang YWHuang MOuyang JHuang LWang JWang QWang XQGu LCai ZHLiu DSWang YCong JCZhan LKang LWu XXu FPZheng XXu QChen GQZeng ZXie MXu FJLi MYang ZLan PGao KHu HYang RLiu HYang XHLu JYChen JHFeng BChinese Transanal Endoscopic Surgery Collaborative (CTESC) GroupHou YGong YLiu XZhou DBLiu YLiu ZLi ZBQian JJYe JWZhang JXRen MSong YXiao YLing LRen DTong WTang RXWu MYHuang ZZhang YZhang XPeng MYTian YFu JCai YLai SLuo SMa DPeng JfalseTransanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial.<h4>Importance</h4>Previous studies have demonstrated the advantages of short-term histopathological outcomes and complications associated with transanal total mesorectal excision (TME) compared with laparoscopic TME. However, the long-term oncological outcomes of transanal TME remain ambiguous. This study aims to compare 3-year disease-free survival of transanal TME with laparoscopic TME.<h4>Objective</h4>To evaluate 3-year disease-free survival between transanal TME and laparoscopic TME in patients with rectal cancer.<h4>Design, setting, and participants</h4>This randomized, open-label, noninferiority, phase 3 clinical trial was performed in 16 different centers in China. Between April 2016 and June 2021, a total of 1115 patients with clinical stage I to III mid-low rectal cancer were en2025-01-01T00:00:00Z2025 Mar2026-03-31T10:29:33.978Z2025-08-23T03:09:30.147ZS-EPMC118809483984736110.1001/jama.2024.24276